Better Buy: Novavax vs. Moderna
Novavax (NASDAQ: NVAX) and Moderna (NASDAQ: MRNA) are two of the biotech industry's biggest success stories from the coronavirus vaccine race. While Moderna's market cap of around $104 billion makes Novavax's $12.6 billion look tiny, that may soon change.
With Novavax's jab racking up approval after approval in recent weeks, revenue will soon start to flood in, just as it did for Moderna. Is Moderna's growth story approaching a plateau just as Novavax is starting its ascent with gusto, or will Moderna manage to increase its momentum? To get a sense of what the answer to that question might be, let's look at the case for each stock.
Image source: Getty Images.
Source Fool.com
